7 juni 2017: omdat ik inhoudelijk alles alleen doe ben ik nog niet toegekomen aan de meeste van deze studies. Enkele wel die zijn verwerkt in onze nieuwsbrief van 7 juni 2017, maar ik wil het zorgvuldig doen en er soms ook bijbehorende informatie bij zoeken. En dat kost gewoon heel veel tijd.

Maar Cancer Research heeft alle studies die te maken hebben met immuuntherapie geselecteerd met link naar abstract. Ik heb hun lijst gekopieerd en per kankersoort ingedeeld op alfabetische volgorde volgens Nederlandse namen:

Verschillende tumorvormen met nadruk op solide tumoren

Alvleesklierkanker

  • The combination of REOLYSIN (oncolytic reovirus immunotherapy) and pembrolizumab (anti-PD-1 checkpoint immunotherapy) along with chemotherapy demonstrated anti-cancer activity in patients with metastatic and relapsed pancreatic cancer. http://abstracts.asco.org/199/AbstView_199_193345.html

  • In a phase I clinical trial, MVT-5873 (anti-CA19-9 antibody immunotherapy) was able to reduce serum levels of CA19-9 and showed signs of effectiveness in patients with CA19-9+ pancreatic cancer. http://abstracts.asco.org/199/AbstView_199_190708.html
  • In a phase I clinical trial, the combination of TG01 (anti-RAS peptide vaccine), GM-CSF (an immunomodulator), and chemotherapy stimulated immune responses in 84% of patients with RAS-mutated pancreatic cancer when the combination was givne after surgery. http://abstracts.asco.org/199/AbstView_199_191964.html

Baarmoederkanker en baarmoederhalskanker:

  • In a phase I/II clinical trial, 20.8% of patients with recurrent/metastatic cancer (cervical, vaginal, or vulvar) responded to nivolumab (anti-PD-1 immunotherapy) treatment, in addition to a 70.8% disease control rate. These responses occurred in both HPV+/- patients, and in tumors both with and without PD-L1 expression. http://abstracts.asco.org/199/AbstView_199_184153.html
  • In a phase I/II clinical trial, an anti-HPV type 16 vaccine in combination with chemotherapy was able to elicit immune responses against HPV antigens in some patients with HPV16+ cervical cancer, and stronger immune responses were correlated increased overall survival. (Cornelis J. M. Melief, M.D., Ph.D., was involved in this work.) http://abstracts.asco.org/199/AbstView_199_192139.html

Blaaskanker:

  • Alterations in the genes responsible for DNA damage repair (DDR), which are associated with higher mutational loads in tumors, was associated with significantly improved responses in patients with metastatic bladder cancer who were treated with anti-PD-1/PD-L1 checkpoint immunotherapy. (Jedd D. Wolchok, M.D., Ph.D., was involved in this work.) http://abstracts.asco.org/199/AbstView_199_191279.html
  • A new tool—the MSI Sensor assay—can help doctors determine the extent to which tumors have deficient DNA mismatch repair (MMR) capability, which is associated with durable responses to checkpoint immunotherapy in patients with advanced bladder cancer. http://abstracts.asco.org/199/AbstView_199_190640.html
  • In a phase I/II clinical trial, the amount of circulating tumor DNA in the blood soon after treatment with durvalumab (anti-PD-L1 checkpoint immunotherapy) decreased in patients who responded, and was associated with increased survival (both overall and progression-free survival). http://abstracts.asco.org/199/AbstView_199_184983.html
  • In a phase III clinical trial, advanced bladder cancer patients treated with pembrolizumab (anti-PD-1 checkpoint immunotherapy) experienced significantly better health-related quality of life and increased overall survival compared to those treated with chemotherapy. (Lawrence Fong, M.D., was involved in this work.) http://abstracts.asco.org/199/AbstView_199_184717.html

Borstkanker:

  • Treating patients with the combination of two anti-HER2 antibody immunotherapies (trastuzumab and pertuzumab) along with a standard chemotherapy regimen before surgery was safe and highly effective for patients with HER2+ early breast cancer. http://abstracts.asco.org/199/AbstView_199_190386.html
  • The radiolabeled 64Cu-DOTA trastuzumab was able to predict responses to treatment with ado-trastuzumab emtansine (an anti-HER2 antibody immunotherapy) in patients with HER2+ metastatic breast cancer. http://abstracts.asco.org/199/AbstView_199_193302.html
  • In a phase II clinical trial, pembrolizumab (anti-PD-1 checkpoint immunotherapy) led to durable responses in some heavily pre-treated patients with metastatic triple-negative breast cancer (TNBC). http://abstracts.asco.org/199/AbstView_199_190305.html
  • In a phase III clinical trial, the immunotherapy trastuzumab emtansine (anti-HER antibody with a toxin attached) was shown to be an effective first-line treatment for patients with HER2+ metastatic breast cancer, and exhibited fewer severe adverse events and an increased median overall survival compared to the standard trastuzumab (anti-HER2 antibody immunotherapy) plus chemotherapy regimen. http://abstracts.asco.org/199/AbstView_199_185945.html
  • In a phase II clinical trial, the combination of pembrolizumab (anti-PD-1 checkpoint immunotherapy) and chemotherapy was able to stimulate immune responses that led to clinical benefits in multiple patients with metastatic triple-negative breast cancer (TNBC). http://abstracts.asco.org/199/AbstView_199_194049.html
  • In a phase II clinical trial, pre-surgery treatment with the combination of dual anti-HER2 antibody immunotherapies (pertuzumab and trastuzumab) along with chemotherapy led to a 78% pathologic complete response rate in patients with either early or late-stage HER2+/ER- breast cancer. http://abstracts.asco.org/199/AbstView_199_190422.html
  • In a phase I clinical trial, ZW25 (a bi-specific antibody immunotherapy that can target two different components of HER2) demonstrated effectiveness in patients with HER2+ breast cancer. http://abstracts.asco.org/199/AbstView_199_188617.html

Darmkanker:

  • A vaccine made from patients’ own tumor cells—which are modified so that they have increased expression of the pro-immune GM-CSF but decreased expression of the immunosuppressive TGF-beta—was capable of promoting a systemic immune response in combination with chemotherapy, and produced long term responses in several patients. http://abstracts.asco.org/199/AbstView_199_187652.html
  • Lower levels of pro-tumor macrophage infiltration were associated with improved responses in patients with advanced colorectal cancer treated with bevacizumab (anti-VEGF antibody immunotherapy), and could serve as a useful biomarker in the future. http://abstracts.asco.org/199/AbstView_199_188312.html
  • In a phase II clinical trial, the combination of pembrolizumab (anti-PD-1 checkpoint immunotherapy) and chemotherapy demonstrated promise as a first-line treatment for patients with advanced colorectal cancer, even for patients whose tumors were DNA mismatch repair proficient (pMMR). http://abstracts.asco.org/199/AbstView_199_183499.html
  • In a phase II clinical trial, dual checkpoint immunotherapy with nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) led to high rates of response and disease control in patients with MSI-hi / DNA mismatch repair deficient (dMMR) colorectal cancer. http://abstracts.asco.org/199/AbstView_199_185252.html

Eierstokkanker:

  • Pre-surgical treatment with bevacizumab (anti-VEGF antibody immunotherapy) in combination with chemotherapy was associated with improved surgical outcomes in patients with advanced, initially unresectable ovarian cancer. http://abstracts.asco.org/199/AbstView_199_186640.html

  • In a phase II clinical trial, patients whose tumors were highly mutated and expressed higher levels of PD-L1 appeared more likely to respond to pembrolizumab (anti-PD-1 checkpoint immunotherapy). http://abstracts.asco.org/199/AbstView_199_186033.html
  • In a phase II clinical trial, vaccination with oregovomab (anti-CA125 antibody immunotherapy) along with chemotherapy was able to enhance anti-tumor immune activity and patient outcomes compared to chemotherapy alone in patients with stage III/IV ovarian cancer. http://abstracts.asco.org/199/AbstView_199_184570.html
  • In a phase I clinical trial, mirvetuximab soravtansine (an antibody-drug conjugate immunotherapy that targets the folate receptor alpha) demonstrated increased clinical benefits compared to chemotherapy for patients with platinum-resistant ovarian cancer. http://abstracts.asco.org/199/AbstView_199_190120.html

Hersentumoren:

Hoofd- en halstumoren / mond- en keelkanker:

  • The combination of rAd-p53 (a recombinant virus designed to transfer the p53 gene into tumor cells) and radiation therapy was shown to decrease both recurrence and metastasis, and increase the disease-free survival rate, over a 7-year follow up period in patients with thyroid cancer. http://abstracts.asco.org/199/AbstView_199_181430.html
  • Improved survival was observed in patients with hypopharyngeal cancer whose tumors lacked PD-L1 expression and were heavily infiltrated by killer T cells. http://abstracts.asco.org/199/AbstView_199_182347.html
  • The combination of cetuximab (anti-EGFR antibody immunotherapy) and chemotherapy appeared to promote antitumor activity in patients with head and neck squamous cell carcinoma (HNSCC) with poor performance status, and its effectiveness was often accompanied by a decrease in certain immunosuppressive microRNAs in the saliva of patients. http://abstracts.asco.org/199/AbstView_199_190690.html

Kinderkanker

Leukemie:

  • CAR (chimeric antigen receptor) T cells targeting the CD19 receptor led to complete responses in two patients with relapsed acute lymphoblastic leukemia (ALL). http://abstracts.asco.org/199/AbstView_199_192547.html
  • Patients with relapsed/refractory acute lymphoblastic leukemia (ALL) who were treated with inotuzumab ozogamicin (an anti-CD22 antibody immunotherapy attached to a toxin) experienced shorter hospital stays after treatment compared to ALL patients treated with the standard of care.  http://abstracts.asco.org/199/AbstView_199_194173.html
  • Patients with relapsed/refractory acute lymphoblastic leukemia (ALL) who were treated with inotuzumab ozogamicin (an anti-CD22 antibody immunotherapy attached to a toxin) experienced an average increase of 2 years in their overall survival adjusted for quality of life. http://abstracts.asco.org/199/AbstView_199_193642.html
  • Combining pembrolizumab (anti-PD-1 checkpoint immunotherapy) with anti-CD19 CAR (chimeric antigen receptor) T cell immunotherapy enhanced survival of the transplanted CAR T cells and led to clinical responses in pediatric patients with relapsed acute lymphoblastic leukemia (ALL). (Carl H. June, M.D., was involved in this work.) http://abstracts.asco.org/199/AbstView_199_187283.html
  • In a phase II clinical trial, CAR (chimeric antigen receptor) T cell immunotherapy was associated with significantly improved quality of life, in addition to an 82% complete response rate, in pediatric and young adult patients with relapsed/refractory acute lymphblastic leukemia. http://abstracts.asco.org/199/AbstView_199_187018.html

Leverkanker:

  • Compared to patients with liver cancer who were treated with surgery alone, liver cancer patients who received cytokine-induced killer (CIK) cells after surgery had significantly improved survival, overall and disease-free, both of which were associated with an increased number of PD-1+ tumor-infiltrating cells. http://abstracts.asco.org/199/AbstView_199_189091.html

Longkanker:

  • In a phase I clinical trial, first-line treatment with the checkpoint immunotherapy combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) was effective for patients with advanced non-small cell lung carcinoma (NSCLC), resulting in six complete responses. Patients whose tumors expressed high levels of PD-L1 were more likely to benefit, but even some patients with minimal PD-L1 expression experienced complete responses. (This work involved Scott J. Antonia, M.D., Ph.D., and Julie R. Brahmer, M.D.)http://abstracts.asco.org/199/AbstView_199_184051.html
  • In a phase I/II clinical trial, the checkpoint immunotherapy combination of epacadostat (anti-IDO1) and pembrolizumab (anti-PD-1) provided benefits for patients with non-small cell lung carcinoma (NSCLC). http://abstracts.asco.org/199/AbstView_199_181148.html
  • In a phase I clinical trial, the combination of AM0010 (PEGylated IL-10 cytokine immunotherapy) and pembrolizumab (anti-PD-1 checkpoint immunotherapy) was effective at activating killer T cells and demonstrated clinical activity in patients with advanced non-small cell lung carcinoma (NSCLC). http://abstracts.asco.org/199/AbstView_199_189952.html
  • In a phase II clinical trial, pembrolizumab (anti-PD-1 checkpoint immunotherapy) led to a 21% response rate and an 80% disease control rate in patients with mesothelioma, regardless of PD-L1 expression. http://abstracts.asco.org/199/AbstView_199_191066.html
  • In a phase II clinical trial, trastuzumab emtansine (anti-HER2 antibody-drug conjugate immunotherapy) led to several responses in patients with HER2-overexpressing advanced/metastatic non-small cell lung carcinoma (NSCLC). http://abstracts.asco.org/199/AbstView_199_186300.html
  • A relationship between EGFR pathway activation, increased CD73 expression, and decreased IFN-gamma expression was found in patients with non-small cell lung carcinoma, and could possibly explain the lack of benefit associated with anti-PD-1/PD-L1 checkpoint immunotherapy in these patients. http://abstracts.asco.org/199/AbstView_199_194449.html

Lymfklierkanker:

Maagkanker en spijsverteringskanker

  • In 99 cases of cholangiocarcinoma, 92% were found to express mesothelin, and the patients whose tumors had low mesothelin expression as well as low infiltration of killer T cells were found to have the poorest prognosis. (Craig L. Slingluff Jr., M.D., was involved in this work.) http://abstracts.asco.org/199/AbstView_199_194002.html
  • Treatment with pembrolizumab (anti-PD-1 checkpoint immunotherapy) led to responses in several patients with mismatch repair-deficient (dMMR) gastrointestinal cancer, including one patient with cholangiocarcinoma who has a complete response.

  • The combination of pembrolizumab (anti-PD-1 checkpoint immunotherapy) and ramucirumab (anti-VEGFR2 antibody immunotherapy) showed promise in patients with gastric adenocarcinoma, both as a first-line treatment and after previous treatment with other therapies. http://abstracts.asco.org/199/AbstView_199_184481.html
  • The presence of microsatellite instability (MSI) or high mutational load (>10 mutations / million base pairs) in the tumors of esophagogastric cancer patients were much more likely to benefit from immunotherapy (either anti-PD-1/PD-L1 checkpoint immunotherapy, or combined anti-PD-1/PD-L1 + anti-CTLA-4 checkpoint immunotherapy). http://abstracts.asco.org/199/AbstView_199_191437.html
  • In a phase I/II clinical trial, the checkpoint immunotherapy combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) provided long-term survival benefits in patients with advanced/metastatic gastroesophageal cancer. (Dung T. Le, M.D., was the senior author of this work, in which Padmanee Sharma, M.D., and Dirk Jaeger, M.D., were also involved.) http://abstracts.asco.org/199/AbstView_199_185268.html

Melanomen:

Multiple Myeloma - ziekte van Kahler / botkanker:

  • Patients with active multiple myeloma were found to have a higher proportion of regulatory T cells with high expression of checkpoint receptors, and the addition of checkpoint immunotherapies (either anti-PD-1, anti-LAG3, or anti-TIM3) were able to promote myeloma-specific anti-tumor activity in these cells. http://abstracts.asco.org/199/AbstView_199_190626.html

Nierkanker:

Prostaatkanker:

  • Expression of the cancer-testis antigen NY-ESO-1 was observed in almost one-third of the prostate cancer patients that were analyzed, suggesting that it could serve as a promising target for immunotherapy. (Kunle Odunsi, M.D., Ph.D., was involved in this work.

Sarcoma - weke delenkanker:

Slokdarmkanker

  • In a phase I clinical trial, the combination of pembrolizumab (anti-PD-1 checkpoint immunotherapy) and ramucirumab (anti-VEGFR2 antibody immunotherapy) showed promise in patients with gastroesophageal junction adenocarcinoma, both as a first-line treatment and after previous treatment with other therapies. http://abstracts.asco.org/199/AbstView_199_184481.html
  • The presence of microsatellite instability (MSI) or high mutational load (>10 mutations / million base pairs) in the tumors of esophagogastric cancer patients were much more likely to benefit from immunotherapy (either anti-PD-1/PD-L1 checkpoint immunotherapy, or combined anti-PD-1/PD-L1 + anti-CTLA-4 checkpoint immunotherapy). http://abstracts.asco.org/199/AbstView_199_191437.html

In a phase I/II clinical trial, the checkpoint immunotherapy combination of nivolumab (anti-PD-1) and ipilimumab (anti-CTLA-4) provided long-term survival benefits in patients with advanced/metastatic gastroesophageal cancer. (Dung T. Le, M.D., was the senior author of this work, in which Padmanee Sharma, M.D., and Dirk Jaeger, M.D., were also involved.) http://abstracts.asco.org/199/AbstView_199_185268.html

Varia aan studies:

  • An online tool was developed to help healthcare providers deal with immune-related adverse events after immunotherapy. Thus far the tool has recommended an alternative course of action in 49% of queries, and 93% of healthcare providers said that they incorporated this advice into their decision making. (Jeffrey S. Weber, M.D., was involved in this work.) http://abstracts.asco.org/199/AbstView_199_190591.html

Plaats een reactie ...

Reageer op "Immuuntherapeutische studies zoals gepresenteerd Op ASCO 2017 in Chicago 2 t/m/ 5 juni 2017"


Gerelateerde artikelen
 

Gerelateerde artikelen

Wetenschappers van het Anthonie >> Nieuw NANO-Vaccin, 2 natuurlijke >> Whole genome sequencing: toekomst >> Darmbacterien beinvloeden >> Surviving terminal cancer: >> AMC start studieproject EIGEN >> Periodieke screening kan veel >> Chemo stimuleert juist kankergroei >> Kanker opsporen binnen 20 >> Effecten van medicijnen en >>